In my last post, I shared about the immense and complex journey of menopause and referenced the New York Times article, “Women Have Been Misled About Menopause.”

Today, I want to take that conversation deeper and explore why so much confusion and fear around menopause treatment still exist—more than 20 years after the Women’s Health Initiative (WHI) study changed the course of how hormone therapy was viewed.

The WHI was a large study published in 2002 that aimed to understand the risks and benefits of hormone replacement therapy (HRT) in postmenopausal women, especially regarding heart disease, cancer, and bone health. Unfortunately, the early headlines reported that HRT increased the risk of breast cancer and heart disease. Many women stopped their medications overnight, and providers became hesitant to prescribe hormones at all.

What was not widely discussed at the time:

• The average age of participants was 63 years old, often more than a decade past menopause onset.
• The study used synthetic, non-bioidentical hormones (conjugated equine estrogen and medroxyprogesterone acetate), which act differently in the body than bioidentical forms.
• Later analyses revealed that women who began hormone therapy closer to menopause—before age 60 or within 10 years of their last period—had lower rates of heart disease and overall mortality.

Since then, additional studies have given us a clearer picture:

• The ELITE Trial showed that starting estradiol early after menopause slowed the progression of atherosclerosis, supporting the “timing hypothesis.”
• Multiple meta-analyses have confirmed that early use of hormone therapy can reduce all-cause mortality and cardiovascular risk in younger postmenopausal women.
• HRT is well-established to protect bone density, reduce fracture risk, support lean muscle, and may offer cognitive and mood benefits.
• Transdermal (through the skin) bioidentical hormones have a lower risk of clotting and are often better tolerated.
• The absolute risks—such as blood clots or breast cancer—are small when therapy is started appropriately and monitored carefully.

In short, not all hormone therapy is the same, and timing, formulation, and route all matter. For many women, the benefits of well-managed hormone therapy far outweigh the risks.

Menopause is not simply an ending—it’s a transition that deserves thoughtful, personalized care. Hormone therapy can be one important part of that care when combined with functional medicine principles that support the whole woman, including nutrition, movement, sleep, stress balance, and emotional and spiritual wellness.



The goal is not just to survive menopause, but to thrive through it—with vitality, clarity, and joy.

In the next post, I will share how we can approach bioidentical hormone therapy safely and effectively—what labs to check, how to monitor progress, and how to integrate it into a whole-body healing plan.

Be well,
Tracy Shulsinger, FNP